查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
亚太地区下一代乳癌诊断与筛检市场：分析与预测（2023-2032）
市场调查报告书
商品编码
1439030

亚太地区下一代乳癌诊断与筛检市场：分析与预测（2023-2032）

Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market: Analysis and Forecast, 2023-2032
出版日期: | 出版商: BIS Research | 英文 82 Pages | 商品交期: 1-5个工作天内

价格

亚太地区下一代乳癌诊断和筛检市场规模预计将从2023年的5.543亿美元成长到2032年的17.794亿美元。

亚太地区下一代乳癌诊断与筛检市场：简介

主要市场统计数据
预测期 2023-2032
2023年评估 5.543 亿美元
2032年预测 17.794 亿美元
复合年增长率 13.84%

预计亚太地区下一代乳癌诊断和筛检市场将显着成长。这一增长是由该地区乳癌发病率上升等因素推动的。活性化以早期检测和筛检为重点的宣传宣传活动也促成了这一激增。此外，人们越来越重视利用乳癌生物标记进行更有效的筛检、预后预测和个人化治疗策略。此外，市场相关人员之间的协作努力和伙伴关係进一步支持诊断技术和筛检方法的进步。在此背景下，亚太地区下一代乳癌诊断和筛检市场为改善全部区域的乳癌管理和结果提供了一个充满希望的机会。

本报告调查了亚太地区下一代乳癌诊断和筛检市场，提供了市场概况、技术趋势、法律制度、市场影响因素分析、市场规模趋势和预测、竞争形势和分析。主要企业等进行了总结。

市场分类

细分 1：按国家/地区

  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 新加坡
  • 其他的

目录

执行摘要

调查范围

第一章 肿瘤分子诊断市场

  • 概述
  • 癌症类型
  • 科技
  • 市场动态
  • 监管部门核准的产品

第二章下一代乳癌诊断与筛检市场

  • 市场展望
    • 产品定义
    • 定义：透过相关技术
    • 包容与排除
    • 概述

第三章 产业展望

  • 主要趋势
    • 液态切片用于乳癌诊断
    • 下一代技术的全自动化
  • 法律规范
    • 美国法规结构
    • 欧洲法规结构
    • 亚太法规结构
  • 监管部门核准的产品
  • 临床试验
  • 乳癌发生率增加（按国家/地区）
  • 不同技术的优点和局限性
  • 价钱

第四章 区域

  • 亚太地区
    • 主要发现
    • 市场动态
    • 市场规模/预测

第五章市场：竞争基准化分析

  • 下一代乳癌诊断和筛检活跃的公司生态系统
  • 公司简介
    • BGI Genomics Co., Ltd.
Product Code: BHP1877SS

The Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Expected to Reach $1,779.4 Million by 2032

Introduction to Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market

KEY MARKET STATISTICS
Forecast Period2023 - 2032
2023 Evaluation$554.3 Million
2032 Forecast$1,779.4 Million
CAGR13.84%

The Asia-Pacific next-generation breast cancer diagnostic and screening market was valued at $554.3 million in 2023 and is anticipated to reach $1,779.4 million by 2032. The anticipated growth in the next-generation breast cancer diagnostic and screening market is projected to be fueled by several factors. These include the uptick in the occurrence of breast cancer cases, heightened awareness concerning early detection of breast cancer, a growing emphasis on breast cancer biomarkers for improved screening, prognosis, and tailored treatment, as well as the escalation in partnerships and collaborations among industry participants.

Market Introduction

The Asia-Pacific (APAC) region anticipates significant growth in the next-generation breast cancer diagnostic and screening market. This growth is propelled by various factors, including the increasing incidence of breast cancer cases in the region. Heightened awareness campaigns focusing on early detection and screening contribute to this surge. Additionally, there's a growing emphasis on utilizing breast cancer biomarkers for more effective screening, prognosis, and personalized treatment strategies. Moreover, the collaborative efforts and partnerships among market players further drive advancements in diagnostic technologies and screening methodologies. With these dynamics in play, the APAC next-generation breast cancer diagnostic and screening market presents promising opportunities for improved breast cancer management and outcomes across the region.

Market Segmentation

Segmentation 1: by Country

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest-of-Asia-Pacific

How can this report add value to an organization?

Growth/Marketing Strategy: The APAC next-generation breast cancer diagnostic and screening market has seen major development by key players operating in the market, such as business expansions, partnerships, collaborations, mergers and acquisitions, product launches, and funding activities. Partnerships, alliances, and business expansions accounted for the maximum number of key developments in the APAC next-generation breast cancer diagnostic and screening market, followed by regulatory and legal activities and mergers and acquisitions.

Competitive Strategy: Key players in the APAC next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, product launches and approvals, and funding scenarios will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Oncology Molecular Diagnostic Market

  • 1.1 Overview
  • 1.2 Cancer Type
  • 1.3 Technology
  • 1.4 Market Dynamics
  • 1.5 Regulatory-Approved Products

2 Next-Generation Breast Cancer Diagnostic and Screening Market

  • 2.1 Market Outlook
    • 2.1.1 Product Definition
    • 2.1.2 Definition by Technologies Involved
      • 2.1.2.1 Real-Time Polymerase Chain Reaction (RT-PCR)
      • 2.1.2.2 Fluorescence In-Situ Hybridization (FISH)
      • 2.1.2.3 Next-Generation Sequencing
      • 2.1.2.4 Immunohistochemistry (IHC)
    • 2.1.3 Inclusion and Exclusion
    • 2.1.4 Overview
      • 2.1.4.1 Market Size and Growth Potential, $Million, 2022-2032

3 Industry Outlook

  • 3.1 Key Trends
    • 3.1.1 Liquid Biopsy for Breast Cancer Diagnosis
    • 3.1.2 Complete Automation of Next-Generation Techniques
  • 3.2 Regulatory Framework
    • 3.2.1 Regulatory Framework in the U.S.
      • 3.2.1.1 FDA Regulation
      • 3.2.1.2 CMS Regulations (Reimbursement Scenario)
    • 3.2.2 Regulatory Framework in Europe
    • 3.2.3 Regulatory Framework in Asia-Pacific
      • 3.2.3.1 China
      • 3.2.3.2 Japan
  • 3.3 Regulatory-Approved Products
  • 3.4 Clinical Trials
  • 3.5 Breast Cancer Incidence Growth Rates (by Country)
  • 3.6 Advantages and Limitations of Different Techniques
  • 3.7 Pricing

4 Regions

  • 4.1 Asia-Pacific
    • 4.1.1 Key Findings
    • 4.1.2 Market Dynamics
      • 4.1.2.1 Impact Analysis
    • 4.1.3 Market Sizing and Forecast
      • 4.1.3.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
        • 4.1.3.1.1 China
          • 4.1.3.1.1.1 Market Dynamics
          • 4.1.3.1.1.2 Market Sizing and Forecast
        • 4.1.3.1.2 Japan
          • 4.1.3.1.2.1 Market Dynamics
          • 4.1.3.1.2.2 Market Sizing and Forecast
        • 4.1.3.1.3 India
          • 4.1.3.1.3.1 Market Dynamics
          • 4.1.3.1.3.2 Market Sizing and Forecast
        • 4.1.3.1.4 Australia
          • 4.1.3.1.4.1 Market Dynamics
          • 4.1.3.1.4.2 Market Sizing and Forecast
        • 4.1.3.1.5 South Korea
          • 4.1.3.1.5.1 Market Dynamics
          • 4.1.3.1.5.2 Market Sizing and Forecast
        • 4.1.3.1.6 Singapore
          • 4.1.3.1.6.1 Market Dynamics
          • 4.1.3.1.6.2 Market Sizing and Forecast
        • 4.1.3.1.7 Rest-of-Asia-Pacific
          • 4.1.3.1.7.1 Market Dynamics
          • 4.1.3.1.7.2 Market Sizing and Forecast

5 Markets - Competitive Benchmarking

  • 5.1 Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
  • 5.2 Company Profiles
    • 5.2.1 BGI Genomics Co., Ltd.
      • 5.2.1.1 Company Overview
      • 5.2.1.2 Role of BGI Genomics Co., Ltd. in the Next-Generation Breast Cancer Diagnostic and Screening Market
      • 5.2.1.3 Financials
      • 5.2.1.4 Recent Developments
      • 5.2.1.5 Analyst Perception

List of Figures

  • Figure 1: Worldwide Breast Cancer Statistics (by Region), 2020
  • Figure 2: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 3: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Technology), $Million, 2022 and 2032
  • Figure 4: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Biomarker), $Million, 2022 and 2032
  • Figure 5: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Sub-Type), $Million, 2022 and 2032
  • Figure 6: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Offering), $Million, 2022 and 2032
  • Figure 7: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by End User), $Million, 2022 and 2032
  • Figure 8: Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
  • Figure 9: Next-Generation Breast Cancer Diagnostic and Screening Market, Key Development Analysis, January 2019-April 2023
  • Figure 10: Next-Generation Breast Cancer Diagnostic and Screening Market: Research Methodology
  • Figure 11: Primary Research Methodology
  • Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 13: Top-Down Approach (Segment-Wise Analysis)
  • Figure 14: Oncology Molecular Diagnostic Market, Solid Tumor, $Million, 2022 and 2032
  • Figure 15: Oncology Molecular Diagnostic Market, Hematological Malignancy, $Million, 2022 and 2032
  • Figure 16: Oncology Molecular Diagnostic Market, Market Dynamics
  • Figure 17: Next-Generation Breast Cancer Diagnostic and Screening Market, Size and Growth Potential, $Million, 2022-2032
  • Figure 18: Market Size and Growth Potential (by Region), $Million, 2022-2032
  • Figure 19: FDA Guidelines for CDx Approval
  • Figure 20: Criteria for CMS Coverage/Reimbursement
  • Figure 21: Europe In-Vitro Diagnostic Devices Regulation Regulatory Process
  • Figure 22: Breast Cancer Incidence Growth Rates (by Country), 2020 and 2040
  • Figure 23: Advantages and Limitations of Different Techniques in the Next-Generation Breast Cancer Diagnostic and Screening Market
  • Figure 24: Next-Generation Breast Cancer Diagnostic and Screening Market Share (by Region), 2022-2032
  • Figure 25: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
  • Figure 26: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 27: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
  • Figure 28: China Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 29: Japan Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 30: India Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 31: Australia Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 32: South Korea Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 33: Singapore Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 34: Rest-of-Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
  • Figure 35: BGI Genomics Co., Ltd. Product Portfolio
  • Figure 36: BGI Genomics Co., Ltd.: Overall Financials, $Million, 2020-2022

List of Tables

  • Table 1: Key Questions Answered in the Report
  • Table 2: Some of the Regulatory-Approved Oncology Molecular Diagnostic Products/Services for Different Types of Solid Tumors
  • Table 3: Some of the Regulatory-Approved Next-Generation Breast Cancer Diagnostic and Screening Products/Tests
  • Table 4: Next-Generation Breast Cancer Diagnostic and Screening, Clinical Trials
  • Table 5: Pricing of Some Products/Services for Next-Generation Breast Cancer Diagnostic and Screening
  • Table 6: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
  • Table 7: Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
  • Table 8: BGI Genomics Co. Ltd.: Key Products and Features